UBX
- Unity Biotechnology, Inc.
()
Overview
Company Summary
Unity Biotechnology, Inc. (UBX) is a biotechnology company focused on developing therapeutics to treat age-related diseases. Unlike traditional medicine that mostly focuses on treating symptoms, UBX aims to target the underlying causes of age-related conditions.
The company utilizes an approach called senescence biology, which involves studying senescent cells. These are cells that have entered a state of irreversible growth arrest due to stress or damage. Although senescent cells are typically cleared by the immune system, as we age, their accumulation becomes more prevalent and can contribute to various age-related diseases.
UBX works to develop small molecule drugs that selectively eliminate senescent cells, a process referred to as senolytic therapy. By removing these harmful cells, the company aims to treat or delay the onset of age-related conditions such as osteoarthritis, kidney disease, eye diseases, and cardiovascular diseases.
UBX's research and development efforts involve identifying specific targets within senescent cells and designing drugs that effectively eliminate them while minimizing any potential side effects. Through their experimental therapies, they aim to improve the health and quality of life for aging individuals.
In summary, Unity Biotechnology, Inc. focuses on developing senolytic therapies to target and remove senescent cells. By doing so, they aim to address the underlying causes of age-related diseases and improve health outcomes in aging populations.